Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Indapamide

FDA-approved product (tablet, oral), marketed as Indapamide, Lozol.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Indapamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Congestive heart failure
  • Hypertension
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sulfonamides, plain
FDA pharmacologic class
Thiazide-like Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA47.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Indapamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Indapamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluating the Use of Oral Indapamide to Reduce Disabiltiy Progression in Progressive Multiple Sclerosis (MS)

    NCT07765212 · start 2026-09

    Registered record
    Registry ID
    NCT07765212
    Conditions
    Multiple Sclerosis
    Interventions
    Indapamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2028-09
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis
    InterventionIndapamide
    PhasePhase 2
    Registry statusNot yet recruiting

  • Polypills Approach for Multiple Cardiovascular Risk Factors

    NCT07679828 · start 2026-07-11

    Registered record
    Registry ID
    NCT07679828
    Conditions
    Hypertension; Dyslipidemia; Diabetes
    Interventions
    Fixed-Dose Combination Strategy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-07-11
    Completion
    2030-03-01
    Enrolment
    8,252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Dyslipidemia; Diabetes
    InterventionFixed-Dose Combination Strategy
    PhaseNot applicable
    Registry statusRecruiting

  • Correlates and Control of Blood Pressure Variability

    NCT06012487 · start 2026-05-01

    Registered record
    Registry ID
    NCT06012487
    Conditions
    Blood Pressure Variability
    Interventions
    Low BPV Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-05-01
    Completion
    2026-12-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBlood Pressure Variability
    InterventionLow BPV Regimen
    PhasePhase 1
    Registry statusNot yet recruiting

  • A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions

    NCT07421414 · start 2026-04-19

    Registered record
    Registry ID
    NCT07421414
    Conditions
    Essential Hypertension
    Interventions
    BR1015-A; BR1015-3; BR1015-2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-04-19
    Completion
    2026-06-17
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionBR1015-A; BR1015-3; BR1015-2
    PhasePhase 1
    Registry statusNot yet recruiting

  • Antihypertensive Drug Selection Based on Hemodynamic Phenotypes

    NCT07240909 · start 2026-01

    Registered record
    Registry ID
    NCT07240909
    Conditions
    Hypertension
    Interventions
    hemodynamics-based individualized antihypertensive therapy; guideline-based conventional treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-01
    Completion
    2026-12
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionhemodynamics-based individualized antihypertensive therapy; guideline-based conventional treatment
    PhasePhase 4
    Registry statusNot yet recruiting

  • Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

    NCT07232966 · start 2025-11-20

    Registered record
    Registry ID
    NCT07232966
    Conditions
    Resistant Hypertension
    Interventions
    Perirenal adipose tissue modification by focused power ultrasound; Sham
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-11-20
    Completion
    2029-06-30
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionResistant Hypertension
    InterventionPerirenal adipose tissue modification by focused power ultrasound; Sham
    PhasePhase 3
    Registry statusNot yet recruiting

  • Treatment With Indapamide in Patients With Post-Surgical Hypoparathyroidism

    NCT07034677 · start 2025-08

    Registered record
    Registry ID
    NCT07034677
    Conditions
    Hypoparathyroidism Post-surgical
    Interventions
    Indapamide 1.5 MG SR; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-08
    Completion
    2025-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypoparathyroidism Post-surgical
    InterventionIndapamide 1.5 MG SR; Placebo
    PhasePhase 4
    Registry statusRecruiting

  • Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

    NCT07064525 · start 2024-12-05

    Registered record
    Registry ID
    NCT07064525
    Conditions
    Hypertension (HTN); NYHA Class III Heart Failure; NYHA Class IV Heart Failure; Diabete Mellitus
    Interventions
    SPC1001 Low; SPC5002; SPC5003; SPC5004
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Enrolling by invitation
    Start
    2024-12-05
    Completion
    2026-02-28
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension (HTN); NYHA Class III Heart Failure; NYHA Class IV Heart Failure; Diabete Mellitus
    InterventionSPC1001 Low; SPC5002; SPC5003; SPC5004
    PhasePhase 2
    Registry statusEnrolling by invitation

  • Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

    NCT06111885 · start 2024-10-01

    Registered record
    Registry ID
    NCT06111885
    Conditions
    Kidney Stone
    Interventions
    Indapamide 2.5 MG; Hydrochlorothiazide 50Mg; Chlorthalidone 25mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-10-01
    Completion
    2027-06-30
    Enrolment
    99

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Stone
    InterventionIndapamide 2.5 MG; Hydrochlorothiazide 50Mg; Chlorthalidone 25mg
    PhasePhase 2
    Registry statusRecruiting

  • European Blood Pressure Intensive Control After Stroke

    NCT04647292 · start 2024-05-02

    Registered record
    Registry ID
    NCT04647292
    Conditions
    Ischemic Stroke; Transient Ischemic Attack
    Interventions
    anti-hypertensive, home blood pressure measurement, telemonitoring and medication titration; Standard of Care Blood Pressure Management with Antihypertensives
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2024-05-02
    Completion
    2026-03
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemic Stroke; Transient Ischemic Attack
    Interventionanti-hypertensive, home blood pressure measurement, telemonitoring and medication titration; Standard of Care Blood Pressure Management with Antihypertensives
    PhasePhase 2
    Registry statusUnknown

  • Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)

    NCT06259175 · start 2024-05-01

    Registered record
    Registry ID
    NCT06259175
    Conditions
    Arterial Hypertension; HTN
    Interventions
    Amlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg; Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg; Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-05-01
    Completion
    2025-06-01
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension; HTN
    InterventionAmlodipine 5 mg + indapamide 1.25 mg + perindopril 5 mg; Amlodipine 5 mg + indapamide 2.5 mg + perindopril 10 mg; Amlodipine 10 mg + indapamide 2.5 mg + perindopril 10 mg
    PhaseNot recorded
    Registry statusCompleted

  • Optimal Medical Treatment of Difficult-to-treat Hypertension

    NCT06275763 · start 2023-10-20

    Registered record
    Registry ID
    NCT06275763
    Conditions
    Hypertension
    Interventions
    Phase C: Eplerenone; Phase C: Spironolactone; Phase C: Torasemide; Phase B: Triplixam / Elestar HCT; Phase A: Confirmation of uncontrolled hypertension
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-10-20
    Completion
    2025-12-31
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionPhase C: Eplerenone; Phase C: Spironolactone; Phase C: Torasemide; Phase B: Triplixam / Elestar HCT +1 more
    PhasePhase 4
    Registry statusUnknown

  • Rapid Management of Resistant Hypertension in the Public Health System (Fast Control)

    NCT07259733 · start 2023-07-15

    Registered record
    Registry ID
    NCT07259733
    Conditions
    Apparent Resistant Hypertension; Hypertension; High Blood Pressure
    Interventions
    Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine); Usual Care Antihypertensive Regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-07-15
    Completion
    2026-12-31
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionApparent Resistant Hypertension; Hypertension; High Blood Pressure
    InterventionTriple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine); Usual Care Antihypertensive Regimen
    PhaseNot applicable
    Registry statusRecruiting

  • OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake

    NCT05780710 · start 2023-06-29

    Registered record
    Registry ID
    NCT05780710
    Conditions
    Hypertension
    Interventions
    Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy and bitherapy); Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy); Aktiia Optical Blood Pressure Monitoring (OBPM) device and individualized antihypertensive treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2023-06-29
    Completion
    2026-12-31
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionAktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy and bitherapy); Aktiia Optical Blood Pressure Monitoring (OBPM) device and antihypertensive drugs (monotherapy); Aktiia Optical Blood Pressure Monitoring (OBPM) device and individualized antihypertensive treatment
    PhaseNot applicable
    Registry statusRecruiting

  • Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India

    NCT05683301 · start 2022-08-30

    Registered record
    Registry ID
    NCT05683301
    Conditions
    Primary Hypertension
    Interventions
    Amlodipine + Perindopril; Perindopril + Indapamide; Amlodipine + Indapamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-08-30
    Completion
    2024-09-22
    Enrolment
    1,981

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Hypertension
    InterventionAmlodipine + Perindopril; Perindopril + Indapamide; Amlodipine + Indapamide
    PhasePhase 4
    Registry statusCompleted